Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus
Incretin hormones are important for the normal functioning of pancreatic islet cells and glucose homeostasis. In type 2 diabetes mellitus, there is a violation of the sensitivity of pancreatic α- and β-cells, which leads to progressive insufficient insulin secretion, insulin resistance due to exces...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Publishing House Zaslavsky
2019-09-01
|
Series: | Mìžnarodnij Endokrinologìčnij Žurnal |
Subjects: | |
Online Access: | http://iej.zaslavsky.com.ua/article/view/185411 |
id |
doaj-3974981abd9643ffa7006d4fa9e4d17c |
---|---|
record_format |
Article |
spelling |
doaj-3974981abd9643ffa7006d4fa9e4d17c2020-11-25T01:31:33ZengPublishing House ZaslavskyMìžnarodnij Endokrinologìčnij Žurnal2224-07212307-14272019-09-0115648248710.22141/2224-0721.15.6.2019.185411185411Possibilities of vildagliptin in optimal control of type 2 diabetes mellitusV.I. Pankiv0MD, PhD, Professor, Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine; e-mail: endocr@i.ua; Web of Science Researcher ID O-6794-2018Incretin hormones are important for the normal functioning of pancreatic islet cells and glucose homeostasis. In type 2 diabetes mellitus, there is a violation of the sensitivity of pancreatic α- and β-cells, which leads to progressive insufficient insulin secretion, insulin resistance due to excessive production of glucagon during periods of postprandial hyperglycemia. In addition, type 2 diabetes mellitus is associated with an increase in lipotoxicity directly related to insulin resistance. The literature review provides data on the safety and efficacy of vildagliptin in patients with type 2 diabetes mellitus, as well as on the pancreatic effects of incretin-targeted therapy. It is clinically confirmed that vildagliptin effectively reduces the level of glycated hemoglobin, has a minimal risk of hypoglycemia and is able to maintain a normal body weight. In addition, vildagliptin inhibits postprandial triglyceride production and decreases fasting lipolysis, possibly affecting the inhibition of lipid absorption and triglyceride stores in non-adipose tissue cells.http://iej.zaslavsky.com.ua/article/view/185411type 2 diabetes mellitusglucagon-like peptide-1glucose-dependent insulinotropic polypeptideinsulin resistancevildagliptinefficiencyreview |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
V.I. Pankiv |
spellingShingle |
V.I. Pankiv Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus Mìžnarodnij Endokrinologìčnij Žurnal type 2 diabetes mellitus glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide insulin resistance vildagliptin efficiency review |
author_facet |
V.I. Pankiv |
author_sort |
V.I. Pankiv |
title |
Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus |
title_short |
Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus |
title_full |
Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus |
title_fullStr |
Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus |
title_full_unstemmed |
Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus |
title_sort |
possibilities of vildagliptin in optimal control of type 2 diabetes mellitus |
publisher |
Publishing House Zaslavsky |
series |
Mìžnarodnij Endokrinologìčnij Žurnal |
issn |
2224-0721 2307-1427 |
publishDate |
2019-09-01 |
description |
Incretin hormones are important for the normal functioning of pancreatic islet cells and glucose homeostasis. In type 2 diabetes mellitus, there is a violation of the sensitivity of pancreatic α- and β-cells, which leads to progressive insufficient insulin secretion, insulin resistance due to excessive production of glucagon during periods of postprandial hyperglycemia. In addition, type 2 diabetes mellitus is associated with an increase in lipotoxicity directly related to insulin resistance. The literature review provides data on the safety and efficacy of vildagliptin in patients with type 2 diabetes mellitus, as well as on the pancreatic effects of incretin-targeted therapy. It is clinically confirmed that vildagliptin effectively reduces the level of glycated hemoglobin, has a minimal risk of hypoglycemia and is able to maintain a normal body weight. In addition, vildagliptin inhibits postprandial triglyceride production and decreases fasting lipolysis, possibly affecting the inhibition of lipid absorption and triglyceride stores in non-adipose tissue cells. |
topic |
type 2 diabetes mellitus glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide insulin resistance vildagliptin efficiency review |
url |
http://iej.zaslavsky.com.ua/article/view/185411 |
work_keys_str_mv |
AT vipankiv possibilitiesofvildagliptininoptimalcontroloftype2diabetesmellitus |
_version_ |
1725086062555955200 |